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Abstract
Background: Exercise-related respiratory symptoms in the diagnosis of exercise-induced
bronchoconstriction (EIB) have poor predictive value. The aim of this study was to evaluate how
athletes presenting with these symptoms are diagnosed and managed in primary care.
Methods: An electronic survey was distributed to a random selection of family practitioners in
England. The survey was designed to assess the frequency with which family practitioners
encounter adults with exercise-related respiratory symptoms and how they would approach
diagnostic work-up and management. The survey also evaluated awareness of and access to
diagnostic tests in this setting and general knowledge of prescribing asthma treatments to
competitive athletes.
Results: 257 family practitioners completed the online survey. One-third of respondents indicated
they encountered individuals with this problem at a frequency of more than one case per month.
Over two-thirds of family practitioners chose investigation as an initial management strategy, while
one-quarter would initiate treatment based on clinical information alone. PEFR pre- and post-
exercise was the most commonly selected test for investigation (44%), followed by resting
spirometry pre- and post-bronchodilator (35%). Short-acting β2-agonists were the most frequently
selected choice of treatment indicated by respondents (90%).
Conclusion: Family practitioners encounter individuals with exercise-related respiratory
symptoms commonly and although objective testing is often employed in diagnostic work-up, the
tests most frequently utilised are not the most accurate for diagnosis of EIB. This diagnostic
approach may be dictated by the reported lack of access to more precise testing methods, or may
reflect a lack of dissemination or awareness of current evidence. Overall the findings have
implications both for the management and hence welfare of athletes presenting with this problem
to family practitioners and also for the competitive athletes requiring therapeutic use exemption.
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Exercise-induced bronchoconstriction (EIB) is highly
prevalent in athletes at all levels of competition and its
diagnosis and treatment is important to ensure their well-
being [1,2]. Accurate diagnosis is essential to avoid mis-
classification and inappropriate treatment [3] and in com-
petitive athletes is particularly important given potential
implications on performance and strict regulations con-
cerning the use of medications [4].
In January 2009, the World Anti-Doping Agency (WADA)
implemented a number of significant changes in their
policy for therapeutic use exemption (TUE) [5], the proc-
ess through which an athlete may be permitted to use an
otherwise prohibited substance to treat a medical condi-
tion. A key change to the policy concerns the TUE proce-
dure for inhaled β2-agonists in asthma or EIB.
The change in the TUE policy will address an important
aspect of EIB, namely the poor correlation between exer-
cise-related respiratory symptoms and objective evidence
of reversible airway narrowing [6,7]. It is currently recog-
nized that clinical assessment alone is often insufficient to
ensure a secure diagnosis of EIB; symptoms have poor pre-
dictive value and there exists a broad differential diagnosis
[8]. Thus, the new policy requires submission of objective
evidence of airway hyperresponsiveness to support diag-
nosis and as such has immediate implications for athletes
but ultimately ramifications for the physicians overseeing
their care.
In the UK, the majority of athletes with exercise-related
respiratory symptoms will be assessed and treated in pri-
mary care. In the 12 months from 1st August 2007 to 31st
July 2008 64% (n = 528) of all TUE applications for
inhaled β2-agonists and corticosteroids were completed
by family practitioners (personal communication, UK
Sport). Of these applications less than 5% provided sup-
porting evidence of reversible airway limitation, indicat-
ing that objective tests may not be commonly utilised in
diagnosis. This assumption is in line with the observed
practise of family practitioners in the US, where it has
been argued that a lack of objective testing in diagnostic
work-up may be leading to inaccurate or missed diagnoses
[9].
Recent reviews highlight the difficulties faced by family
practitioners when evaluating exercise-induced respira-
tory disorders [10], but problems may also arise because
of an insufficient awareness or lack of access to appropri-
ate tests. Currently however, exactly how family practi-
tioners diagnose and manage athletes with suspected EIB
remains undefined. We therefore conducted a survey of
family practitioners in England designed to evaluate their
clinical knowledge and approach to an athlete presenting
with exercise-related respiratory symptoms suggestive of
EIB.
Methods
Survey design and population
An electronic survey was designed to be distributed to
family practitioners to explore the following aspects of
diagnosis and management of exercise-related respiratory
symptoms suggestive of EIB:
1) Frequency of consults of exercise-related respiratory
symptoms in adults.
2) Strategies employed in diagnosis and management of a
clinical scenario of suspected EIB.
3) Awareness of and access to tests used in diagnosis of
EIB.
4) General knowledge of prescribing treatment for EIB in
competitive athletes.
Data was collected over a six month period between Feb-
ruary and July 2008. Surveys were anonomysed and proc-
essed by an independent analysis facility
(Surveymonkey.com). The study was approved by the
university research ethics committee (SUB_LA_1207) and
all respondents were required to indicate informed con-
sent before they were allowed to continue with the survey.
Respondents were not compensated for completing the
survey. Only fully completed surveys were used in final
analysis.
Survey instrument
The survey consisted of one clinical scenario (see below)
and a series of multiple-choice questions. The scenario
was based on a clinical presentation of an athlete with
exercise-related respiratory symptoms encountered in pri-
mary care practice by one of the authors.
A 24-yr-old competitive cyclist consults you complaining of
'difficulty breathing' when exercising. He says symptoms
start shortly after starting riding and reports difficulty
'catching his breath'. He also reports hearing occasional
wheeze. He has no other medical history and otherwise feels
very well. Examination and peak flow are normal. What is
your next management step?
• Advise reduction in exercise exposure
• Arrange further testing
• Prescribe treatmentPage 2 of 7
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arranged
• Refer to specialist
In order to simulate 'real-life' clinical practise and hence
allow insight into investigation and management choices
the questions within the survey had built-in logic steps i.e.
successive questions were based on previous answers. This
allowed an 'interactive' and hence more representative
assessment of how family practitioners would approach
the clinical scenario. It also permitted a further evaluation
of management choice when respondents were provided
with test results indicating no evidence of airway hyperre-
sponsiveness (i.e. not fulfilling criteria to support a diag-
nosis of EIB) or when presented with a later re-consult
with ongoing symptoms. The order in which the possible
choices were presented was randomised for each respond-
ent to avoid response bias. The survey did not permit
respondents to revise their answers retrospectively.
Face validity was assessed in a pilot survey distributed to a
cohort of twenty family practitioners with adjustments
made prior to distribution of the final survey.
Survey distribution
The survey was distributed as an electronic e-mail link, via
primary care trusts (PCTs) to their e-mail distribution list
of registered family practitioners/primary care practice
managers. A random selection of representative PCTs in
England were approached and 90% agreed to distribu-
tion. The nature of the distribution method did not allow
an evaluation of successful delivery of e-mails and hence
a determination of response rate. Furthermore the survey
was only granted distribution on a single occasion within
each PCT.
Statistical analysis
Analysis of data is predominantly descriptive. Investiga-
tion of the influences of frequency of encounter (high (≥
11 per year) and low (<11 per year)) and region (north,
midlands, south) on responses were assessed using either
Fisher's Exact Test (2 × 2) or Chi-squared Test for Inde-
pendence. All percentages are rounded to the nearest inte-
ger. Significance was accepted at p < 0.05.
Results
Distribution and response rate
269 family practitioners started the survey and 257 (96%)
completed the survey.
Frequency of consult
Respondents' answers to the question 'Approximately how
many patients a year do you see complaining of respiratory
symptoms occurring during dedicated exercise?' are shown in
Figure 1. 35% of respondents indicated that they encoun-
tered at a frequency corresponding to at least one case per
month. There were no regional differences in the fre-
quency (i.e. high or low) of cases (p = 0.14).
Strategies employed in diagnosis and management of 
clinical scenario
The management strategy selected by family practitioners
when faced with the clinical scenario is illustrated in Fig-
ure 2. The choice of initial management strategy did not
relate to frequency of encounter reported in the first ques-
tion (p = 0.89).
Choice of test
No respondents selected a bronchoprovocation test as an
initial investigation. Choice of the three most commonly
selected tests namely: PEFR; spirometry pre and post
bronchodilator (spiroBD); and spirometry pre and post
exercise (spiroEX), did not relate to consult frequency (p
= 0.59) or geographical region (p = 0.45).
Respondents indicated they would select "other" investi-
gations in 4% of cases. These included: a trial of inhaled
β2-agonist during exercise, serial peak flow monitoring,
peak flow with reversibility testing and in one case full
blood count, chest radiograph, electrocardiogram and
echocardiogram. The 'next-step' management strategy
selected when respondents were presented with a test
result that did not support diagnosis of EIB (e.g. 'there is
less than 10% difference in PEFR before and after exercise') is
shown in Figure 3.
Choice of treatment
90% of practitioners chose short-acting β2-agonists
(SABA) as their initial treatment option and 2% selected
Frequency of consult with exercise-related respiratory symp-tomsigur  1
Frequency of consult with exercise-related respira-
tory symptoms.Page 3 of 7
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3% of cases respondents indicated initial treatment with
long-acting β2-agonists (LABA) without ICS if faced with
this clinical scenario with 2% choosing LABA combined
with ICS. A further 2% selected to treat with ICS on its
own and 2% chose leukotriene receptor antagonists. No
respondents selected oral corticosteroid, anti-choliner-
gics, sodium cromoglycate (cromones) or theophyllines
(xanthines). Analysis was performed for those who
selected empirical treatment as to management strategy at
a re-consult two months later – 'The cyclist returns to see you
2 months later complaining of ongoing symptoms and feels that
they are limiting his performance. What is your next manage-
ment step' (Figure 4). The instance of ICS treatment
increased from 6% at initial consult to 75% at re-consult.
Access to objective tests
In response to the question, 'To which of the following
test(s), used in the diagnosis of exercise-induced bronchocon-
striction, do you have access?', 11% of the family practition-
ers indicated they have access to laboratory exercise
testing while only 4% have access to eucapnic voluntary
hyperpnea (EVH), metacholine or mannitol provocation
testing. 85% of respondents had no access to any bron-
choprovocation tests.
Management strategy of clinical scenarioFigur  2
Management strategy of clinical scenario. Definition of 
abbreviations: SpiroEX = spirometry pre and post exercise; 
SpiroBD = spirometry pre and post bronchodilator; 
SpiroREST = spirometry at rest; PEFR = peak flow pre 
and post exercise; SABA = short-acting β2-agonist.
Management strategy following an inconclusive initial test result (i.e. ot supportive of EIB)Fig r  3
Management strategy following an inconclusive ini-
tial test result (i.e. not supportive of EIB).
Management strategy at re-consult following initial empirical treatmentFigur  4
Management strategy at re-consult following initial 
empirical treatment.Page 4 of 7
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competitive athletes
Responses to the question 'which of the following medica-
tions is a competitive cyclist permitted to use without notifying
their governing body?' are shown in Table 1. 8% of respond-
ents thought that none of the medications were permitted
for use without notification while 66% of respondents felt
unsure.
Discussion
The results from this survey indicate that it is common for
family practitioners to encounter individuals with exer-
cise-related respiratory symptoms; with over a third
reporting at least one case per month. When faced with
such a scenario nearly three quarters of respondents
(71%) indicated they would select objective testing to
diagnose EIB. However the most commonly selected tests,
namely exercise PEFR (44%) and spirometry with bron-
chodilator (35%), have been found to have poor diagnos-
tic accuracy for EIB [11,12]. In addition, a quarter of
family practitioners (23%) indicated they would treat
empirically based upon clinical features alone. Overall
this raises concern that diagnosis of EIB may be inaccurate
or indeed missed [6,7] and as such, these findings have
implications for the welfare of athletes with this problem.
They also have ramifications for competitive athletes
given the mandatory requirement for objective evidence
in application for inhaled β2-agonists TUE from Jan 2009;
perhaps in particular for those athletes who may apply to
renew their TUE on the back of an unsound initial diagno-
sis.
The International Olympic Committee-Medical Commis-
sion (IOC-MC) has recently renewed its consensus guide-
lines for the diagnosis of EIB in athletes with respiratory
symptoms [13]. It is recommended that athletes with
abnormal baseline spirometry (FEV1 < 80%, FEV1/FVC <
0.7) should be investigated initially with a bronchodilator
challenge and otherwise with a bronchoprovocation chal-
lenge; the latter being defined as a test with the purpose of
evaluating change in airway calibre in response to an air-
way challenge (e.g. exercise, EVH, methacholine, or man-
nitol provocation).
This guidance is based on the fact that bronchodilator
testing in athletes is unlikely to detect airway reversibility
in those with normal resting spirometry [1] and that bron-
choprovocation testing has the highest sensitivity and spe-
cificity for diagnosis [14]. The IOC-MC guidelines also
underline use of FEV1 as a marker of airway narrowing [8]
given that use of PEFR may lead to misclassification [11]
and as such is no longer recommended in guidelines or
accepted by WADA. Please see relevant section in http://
www.100percentme.co.uk for approach and algorithm
recommended for UK athletes.
The choice of objective tests made by family practitioners
when faced with this problem appears at odds with these
recommendations. Bronchoprovocation was not selected
by any respondent as a test of preference and PEFR was the
most commonly used measure of airway narrowing. A key
reason for this appears to be the limited access to bron-
choprovocation challenges in primary care. In our cohort,
85% of family practitioners have no access to any sort of
bronchoprovocation testing; 11% have access to labora-
tory-based exercise tests while only 4% reported access to
EVH, methacholine or mannitol provocation testing. Our
findings are supported by the UK TUE applications com-
pleted by family practitioners, which indicated PEFR in
28% of cases, spirometry in 3% and bronchoprovocation
in 0.05% (personal communication, UK Sport). In con-
trast sports medicine specialists completing the TUE
application provided supporting evidence of diagnosis
with bronchoprovocation in 14% of cases. This may relate
to differences in patient populations; however, does high-
light the fact that the physicians most likely to initially
encounter individuals with this condition have least
access to the most accurate diagnostic tests. Furthermore,
as of January 2009, the lack of access to these tests has
important implications for the preparation of a medical
file to fulfil the criteria for TUE and as such potentially
limits the ability of family practitioners to manage com-
petitive athletes with this problem.
The approach to an athlete with suspected EIB by family
practitioners in England appears to contrast with that of
family practitioners in the US [9]. On presentation of a
similar case scenario, 81% of family practitioners in the
US opted for empirical treatment and 18% for investiga-
tion vs. 23% and 72% respectively, in our study cohort.
The practise of family practitioners in England appears
more in line with US pulmonologists who were four-fold
more likely than the family practitioners to employ testing
initially. However, it should be noted that the US survey
Table 1: Responses to the question 'which of the following 
medications is a competitive cyclist permitted to use without 
notifying their governing body?
Medication Responses (%)
Inhaled short-acting β2-agonists 20
Inhaled long-acting β2-agonists 14
Inhaled corticosteroid 9
Inhaled corticosteroid and short-acting β2-agonists 7
Inhaled corticosteroid and long-acting β2-agonists 6
Oral corticosteroid 1
Leukotriene receptor antagonists 18
Anticholinergics 11
Sodium cromoglycate 18
Theophyllines 4Page 5 of 7
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of investigation and in no instance was this method
selected by responders in this study
When initiating treatment the vast majority of family
practitioners in England (90%) indicated they would ini-
tiate treatment with a SABA alone. This is in line with
guideline recommendations [12] and with reports of sim-
ilar therapy preference in US family practitioners [9] and
Finnish doctors [15]. In the treatment of EIB in athletes it
is increasingly recognised that treatment with β2-agonists
alone may not be adequate and has problems including
tachyphylaxis and unfavourable side effects [16]. Further-
more, given the fact that there is recognised inflammatory
component [17] and that athletes require medication reg-
ularly it has been recommended that early initiation of
ICS is preferable [12]. In this study, 6% of family practi-
tioners indicated they would initially treat with ICS,
although this rose to 75% when faced with a re-consult at
two months. Perhaps alarmingly, given the recommenda-
tions not to prescribe LABA without ICS, 3% of family
practitioners chose this treatment strategy. Interestingly,
despite an 'other' option being available in the answer sec-
tion, no respondents indicated alternative recognized
treatment options such as a warm-up [18], avoidance of
triggers [2] or dietary modification [19,20]. Further work
is needed to determine whether this may reflect a defini-
tive choice on the part of family practitioners or be the
result of a lack of dissemination or awareness of current
evidence or teaching of sport and exercise medicine in
England [21].
The approach chosen by many respondents to initiate
treatment empirically is confounded by the poor correla-
tion between subjective symptoms and objective evidence
of airway narrowing [7]. It also presents a number of diag-
nostic difficulties if an individual represents with ongoing
symptoms. The PRACTALL guidelines recommended that
if EIB treatment is not successful then other diagnoses
should be re-considered including vocal cord dysfunction,
arterial hypoxemia and general poor physical fitness [10].
However, other possibilities include: insufficient treat-
ment; poor therapy compliance; or ineffective inhaler
technique. To explore this further we represented the ath-
lete at two months after initiation of empirical treatment.
Interestingly, almost half of respondents opted to arrange
investigation at this point, whilst only one third opted to
change treatment.
In treating competitive athletes, the majority of respond-
ents (66%) indicated they were unsure which medica-
tion(s) a competitive athlete (in this scenario a cyclist)
was permitted to use without notifying their governing
body (Table 1). These findings are in keeping with previ-
ous surveys of family practitioners in the UK and France
suggesting a limited knowledge of the implications of pre-
scribing medication to this specialist population [22,23].
Although the onus remains on the athlete to inform a gov-
erning body of prohibited medication use, physicians
should be aware of the process especially given the
changes in the requirements for a medical file for TUE
from January 2009.
Our study has a number of limitations. Firstly, similar to
the report by Parsons and colleagues [9] the methods
employed to distribute the survey meant that we were
unable to accurately assess response rate. An electronically
distributed method was selected in order to allow realistic
feedback however as such did not allow us to determine
delivery confirmation. To our knowledge, this study is the
first to use this approach to survey family practitioners
nationwide using the electronic e-mail database. We have
no reason to believe bias in one direction within
responses and furthermore our findings are supported by
family practitioner completed TUE applications. Sec-
ondly, the wording of case scenario was selected to be sug-
gestive of EIB, however it is acknowledged that the
differential diagnosis is broad and potentially includes
other respiratory and cardiac pathologies. We therefore
provided an 'other' option and correspondingly a small
proportion of family practitioners selected investigations,
such as chest radiographs and electrocardiographs.
Finally, the methods employed only permitted a single
distribution of the survey. As such the findings would be
supported and further validated by repeating assessment
on an additional occasion.
Conclusion
The findings from this study provide an insight into the
manner in which athletes with exercise-related respiratory
symptoms are diagnosed and managed in primary care.
The results indicate that although some form of objective
testing is often employed in diagnostic work-up, the tests
most frequently employed are not the most accurate for
the diagnosis of EIB.
Overall the findings have implications for the manage-
ment and hence welfare of athletes presenting with exer-
cise-related respiratory symptoms to primary care but also
have important implications for competitive athletes
requiring medical evidence in support of TUE application.
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